This included confirmed partial responses in two patients: one with endometrial adenocarcinoma harboring a PIK3R2 alteration, and one with ovarian carcinoma harboring a PIK3CA and PTEN alterations. This evidence concerns the gene PIK3CA and ovarian carcinoma.